within Pharmacolibrary.Drugs.ATC.J;

model J01DE51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 4.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,
    adminCount     = 1,
    Vd             = 0.013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cefepime is a fourth-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It is often combined with a beta-lactamase inhibitor (such as tazobactam or zidebactam) to extend its activity against beta-lactamase-producing bacteria. These combinations are typically used in treatment of complicated urinary tract infections, hospital-acquired pneumonia, and other serious infections. As of now, cefepime-beta-lactamase inhibitor combinations (ATC J01DE51) are not widely approved as co-formulations, and clinical use may be limited to investigational or compassionate settings.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data available specifically for cefepime and a beta-lactamase inhibitor combination. The following parameters are estimated based on known pharmacokinetics of cefepime (adult, intravenous administration, normal renal function) and commonly used beta-lactamase inhibitors.</p><h4>References</h4><ol><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2024). Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination. <i>Drugs</i> 84(10) 1219–1250. DOI:<a href=&quot;https://doi.org/10.1007/s40265-024-02082-9&quot;>10.1007/s40265-024-02082-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39214942/&quot;>https://pubmed.ncbi.nlm.nih.gov/39214942</a></p></li><li><p>Dowell, JA, et al., &amp; Henkel, T (2021). Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor. <i>Antimicrobial agents and chemotherapy</i> 65(11) e0105321–None. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01053-21&quot;>10.1128/AAC.01053-21</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34370573/&quot;>https://pubmed.ncbi.nlm.nih.gov/34370573</a></p></li><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> 79(3) 271–289. DOI:<a href=&quot;https://doi.org/10.1007/s40265-019-1055-2&quot;>10.1007/s40265-019-1055-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30712199/&quot;>https://pubmed.ncbi.nlm.nih.gov/30712199</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DE51;
